• 1.

    Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K, Johnson EM, Borman A; Candida auris incident Management Team, Manuel R, Brown CS, 2018. Candida auris: a review of the literature. Clin Microbiol Rev 31: e00029-17.

    • Search Google Scholar
    • Export Citation
  • 2.

    Schelenz S 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5: 35.

    • Search Google Scholar
    • Export Citation
  • 3.

    Magobo RE, Corcoran C, Seetharam S, Govender NP, 2014. Candida auris-associated candidemia, South Africa. Emerg Infect Dis 20: 12501251.

  • 4.

    Chowdhary A 2014. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33: 919926.

  • 5.

    CDC, 2019. General Information about Candida auris | Candida auris | Fungal Diseases. Available at: https://www.cdc.gov/fungal/candida-auris/candida-auris-qanda.html. Accessed November 19, 2019.

    • Search Google Scholar
    • Export Citation
  • 6.

    European Centre for Disease Prevention and Control, 2018. Rapid Risk Assessment: Candida auris in Healthcare Settings – Europe. Available at: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-candida-auris-healthcare-settings-europe. Accessed November 19, 2019.

    • Search Google Scholar
    • Export Citation
  • 7.

    GOV.UK, 2016. Candida auris: Laboratory Investigation, Management and Infection Prevention and Control. Available at: https://www.gov.uk/government/publications/candida-auris-laboratory-investigation-management-and-infection-prevention-and-control. Accessed November 19, 2019.

    • Search Google Scholar
    • Export Citation
  • 8.

    Snyder GM, Wright SB, 2019. The epidemiology and prevention of Candida auris. Curr Infect Dis Rep 21: 19.

  • 9.

    Bidaud AL, Chowdhary A, Dannaoui E, 2018. Candida auris: an emerging drug resistant yeast–a mini-review. J Mycol Med 28: 568573.

  • 10.

    Ledwoch K, Maillard JY, 2018. Candida auris dry surface biofilm (DSB) for disinfectant efficacy testing. Materials (Basel) 12: 18.

  • 11.

    Maurand A, Gagnaire J, Berthelot P, 2018. Candida auris: émergent, multi-résistant, nosocomial, transmissible. Bulletin National du Centre de Prévention des infections associées aux soins (CPias) n°10. Available at: http://www.cpias.fr/bulletin/2018/10/10-pdf/10-tous_les_articles.pdf.

    • Search Google Scholar
    • Export Citation
  • 12.

    Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST)*. Clin Microbiol Infect 18: E246E247.

    • Search Google Scholar
    • Export Citation
  • 13.

    de Groot T, Puts Y, Berrio I, Chowdhary A, Meis JF, 2020. Development of Candida auris Short tandem repeat typing and its application to a global collection of isolates. mBio 11: e02971-19.

    • Search Google Scholar
    • Export Citation
  • 14.

    Rudramurthy SM 2017. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother 72: 17941801.

  • 15.

    Chakrabarti A 2015. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41: 285295.

  • 16.

    Lockhart SR 2017. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64: 134140.

    • Search Google Scholar
    • Export Citation
  • 17.

    Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A, 2017. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother 61: e00485-17.

    • Search Google Scholar
    • Export Citation
  • 18.

    de Groot T, Puts Y, Berrio I, Chowdhary A, Meis JF, 2019. Development of Candida auris microsatellite typing and its application on a global collection of isolates. bioRxiv. 792663. doi: 10.1101/792663.

    • Search Google Scholar
    • Export Citation
  • 19.

    Vallabhaneni S 2016. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus–United States, May 2013–August 2016. MMWR Morb Mortal Wkly Rep 65: 12341237.

    • Search Google Scholar
    • Export Citation
  • 20.

    Moore G, Schelenz S, Borman AM, Johnson EM, Brown CS, 2017. Yeasticidal activity of chemical disinfectants and antiseptics against Candida auris. J Hosp Infect 97: 371375.

    • Search Google Scholar
    • Export Citation
  • 21.

    Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP, 2017. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol 55: 29963005.

    • Search Google Scholar
    • Export Citation
  • 22.

    Sauget M, Valot B, Bertrand X, Hocquet D, 2017. Can MALDI-TOF mass spectrometry reasonably type bacteria? Trends Microbiol 25: 447455.

  • 23.

    Quéro L, Courault P, Cellière B, Lorber S, Jany JL, Puel O, Girard V, Vasseur V, Nodet P, Mounier J, 2020. Application of MALDI-TOF MS to species complex differentiation and strain typing of food related fungi: case studies with Aspergillus section flavi species and Penicillium roqueforti isolates. Food Microbiol 86: 103311.

    • Search Google Scholar
    • Export Citation
  • 24.

    Al-Hatmi AMS, Normand AC, van Diepeningen AD, Hendrickx M, de Hoog GS, Piarroux R, 2015. Rapid identification of clinical members of Fusarium fujikuroi complex using MALDI-TOF MS. Future Microbiol 10: 19391952.

    • Search Google Scholar
    • Export Citation

 

 

 

 

 

Case Report: Emergence of Candida auris in the Indian Ocean Region

View More View Less
  • 1 Réanimation Polyvalente, Centre Hospitalier Universitaire La Réunion, Saint-Denis, France;
  • 2 Laboratoire de Bactériologie, Centre Hospitalier Universitaire La Réunion, Saint-Denis, France;
  • 3 UMR Processus Infectieux en Milieu Insulaire Tropical (PIMIT), CNRS 9192, INSERM U1187, IRD 249, Université de La Réunion, Saint-Denis, France;
  • 4 CLIN, Centre Hospitalier Universitaire La Réunion, Saint-Denis, France;
  • 5 Molecular Mycology Unit, National Reference Center for Invasive Mycoses and Antifungals, Institut Pasteur, CNRS, UMR2000, Paris, France;
  • 6 Département d’informatique Clinique, Centre Hospitalier Universitaire La Réunion, Saint-Denis Cedex, France

ABSTRACT

Candida auris is an emerging multidrug-resistant yeast that can cause severe infections and spread easily between hospitalized patients, leading to outbreaks in hospital. Here, we report the first four cases of colonization and invasive infection with C. auris reported in the Indian Ocean region. All cases were observed in the French overseas Reunion Island, a very popular destination for European travelers. Three patients had urinary tract or skin colonization, and one had a fatal invasive infection. In three cases, including that of the infected patient, the yeast was not initially identified as C. auris, preventing specific hygiene measures to be implemented as suggested in the December 2016 clinical alert to European healthcare facilities. The infected patient likely acquired C. auris in the intensive care unit from the first colonized patient. This is the first case of C. auris infection and the first potential case of nosocomial transmission of the pathogen to be reported in the French overseas Reunion Island.

Author Notes

Address correspondence to Yaël Levy, Réanimation Polyvalente, Centre Hospitalier Universitaire La Réunion, Allée des Topazes, 97400, Saint-Denis, La Réunion, France. E-mail: l.yael@hotmail.fr

Authors’ addresses: Yaël Levy, Laura Teysseyre, Nicolas Allou, and Jérôme Allyn, Intensive care unit, Reunion University Hospital Center, Saint-Denis, France, E-mails: l.yael@hotmail.fr, laura.teysseyre@gmail.com, nicolas.allou@hotmail.fr, and jerome.allyn@chu-reunion.fr. Guillaume Miltgen and Nicolas Traversier, Department of bacteriology, Reunion University Hospital Center, Saint-Denis, France, E-mails: guillaume.miltgen@chu-reunion.fr and nicolas.traversier@chu-reunion.fr. Alexandra Rousseau and Nathalie Lugagne, Nosocomial infection unit, Reunion University Hospital Center, Saint-Denis, France, E-mails: alexandra.rousseau@chu-reunion.fr and nathalie.lugagne@chu-reunion.fr. Marie Desnos-Ollivier, Department of Mycology, Pasteur Institute, Paris, France, E-mail: marie.desnos-ollivier@pasteur.fr.

Save